Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$25M
- −95.7% YoY · +5.2% QoQ
- EPS (diluted)
- −$0.54
- −42.1% YoY · +5.3% QoQ
Source: XBRL data from the CAPRICOR THERAPEUTICS, INC. (CAPR) Q3 2025 10-Q on SEC EDGAR. USD.
CAPRICOR THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New legal risk: securities class action, derivative claims, and Section 220 Demand initiated by stockholders, increasing litigation costs and management distraction
- Updated regulatory risk: heightened focus on clinical trial outcomes and approvals due to dependency for business success
- Operational risk: potential management diversion from business strategies linked to responding to stockholder litigation
- Market risk: risk of decline in common stock price driven by ongoing litigation challenges
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CAPRICOR THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.